Nuwellis stock analysis
Want to see NUWE full AI Analyst Report?
Nuwellis (NUWE) Stock Price & Analysis
NUWE Stock Chart & Stats
- Day’s Range
- $3.83 - $4.12
- 52-Week Range
- $2.52 - $1,555.79
- Previous Close
- $4.10
- Volume
- N/A
- Average Volume (3M)
- 1.41M
- Market Cap
- $2.10M
- Enterprise Value
- -$5.95M
- Total Cash (Recent Filing)
- $8.29M
- Total Debt (Recent Filing)
- $135.00K
- Price to Earnings (P/E)
- ―
- Beta
- 1.94
- Next Earnings
- Mar 02, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Recurring Revenue Model
Aquadex combines system placements with recurring circuit purchases, linking revenue to procedure utilization rather than one-time equipment sales alone. The installed base and presence across about 135 hospital accounts can support repeat demand and deepen customer relationships as clinical adoption expands.
Pediatric And Revenue Growth
Growth in revenue, console placements, and pediatric sales indicates expanding adoption in a strategically important segment. More installed consoles can enlarge the future consumables base, while pediatric momentum broadens the company’s clinical reach and supports longer-term utilization growth.
Improving Gross Margin And Costs
Higher gross margin alongside lower operating expenses shows progress toward a more efficient operating model. If sustained as product mix and scale improve, these gains can reduce the earnings burden from the company’s fixed cost base and strengthen its path toward better cash conversion.
Bears Say
Persistent Cash Burn
Materially negative operating and free cash flow means the business is consuming cash to operate rather than funding itself internally. Continued burn can restrict investment flexibility and increase reliance on additional financing before the company reaches sustainable profitability.
Deep Operating Losses
Strong gross margin has not yet translated into viable overall economics because operating expenses remain far above gross profit. Persistently large operating and net losses indicate that substantial growth or further cost reductions are required before the model can approach break-even.
Unstable Top-Line Performance
The broader revenue contraction and uneven quarterly performance make the growth trajectory less dependable. Flat revenue and lower console sales can slow expansion of the installed base and reduce the pace at which recurring circuit revenue develops over the next several quarters.
Nuwellis News
NUWE FAQ
What was Nuwellis’s price range in the past 12 months?
What is Nuwellis’s market cap?
When is Nuwellis’s upcoming earnings report date?
How were Nuwellis’s earnings last quarter?
Is Nuwellis overvalued?
Does Nuwellis pay dividends?
What is Nuwellis’s EPS estimate?
How many shares outstanding does Nuwellis have?
What happened to Nuwellis’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Nuwellis?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Nuwellis
Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company provides Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure, as well as Aquadex SmartFlow system for temporary use in adult and pediatric patients. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Michael McCormick
- Employees
- 38
- Website
- www.nuwellis.com
- Address
- 12988 Valley View Road, Eden Prairie, MN, 55344, US
Nuwellis (NUWE) Earnings & Revenues
NUWE Earnings Call
Earnings Call SentimentPositive
The call was predominantly positive. Management highlighted double-digit year-to-date revenue growth, an 88% increase in console sales, pediatric growth, substantial gross-margin expansion, lower operating expenses, regulatory progress, new commercial agreements, a developing 2027 product pipeline, and strengthened liquidity. These positives were partially offset by flat third-quarter revenue, lower quarterly console sales, a continued operating loss, a net loss, and challenging second-half comparisons.
View all NUWE earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 3 | 15 |
| Technical Analysis | 4 | 3 | 3 |
| Moving Averages | 0 | 0 | 12 |













